TherapeuticsMD Turns To Profit In Q2 - Quick Facts

(RTTNews) - TherapeuticsMD, Inc. (TXMD), a women's healthcare company, reported Monday that its second-quarter net income was $112.28 million or $12.39 per share, compared to net loss of $42.65 million or $5.41 per share a year ago.

Total net revenue grew to $28.56 million from last year's $23.00 million.

Hugh O'Dowd, CEO of TherapeuticsMD, said, ""We saw solid revenue growth during the quarter, with an increase of 24% over the prior year period, while also experiencing a 21% decrease in operating expenses. The U.S. Food and Drug Administration's recent approval of our supplemental new drug application for ANNOVERA has significantly enhanced our ability to meet demand for the product."

The company said it recently repaid $120 million dollars of debt with the proceeds of divestiture of vitaCare unit.

In pre-market activity on Nasdaq, TherapeuticsMD shares were trading at $9.97, up 8.25 percent.